Anzeige
Meldung des Tages: Erste Psilocybin-Behandlungen laufen – warum steht Optimi noch bei Pennystock-Level?!

VolitionRX News

Aktie
WKN:  A12B6K ISIN:  US9286611077 US-Symbol:  VNRX Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
0,22325 $
-0,0139 $
-5,88%
0,1889 € 27.02.26
Depot/Watchlist
Marktkapitalisierung *
22,85 Mio. €
Streubesitz
62,90%
KGV
-1,94
Index-Zuordnung
-

VolitionRX News

25.02.26 - PR Newswire
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
VolitionRx Highlights Commercial Momentum and Multi-​Pillar Execution PR Newswire
10.02.26 - PR Newswire
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
Volition Announces the Appointment of New Distributor for Nu.Q® Discover PR Newswire
09.02.26 - PR Newswire
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
VolitionRx Receives Notice of Non-​Compliance with NYSE American Continued Listing Standards PR Newswire
04.02.26 - PR Newswire
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation PR Newswire
30.01.26 - PR Newswire
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays PR Newswire
27.01.26 - PR Newswire
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication PR Newswire
20.01.26 - PR Newswire
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test PR Newswire
16.01.26 - PR Newswire
Volition Sponsors Symposium at Veterinary Meeting and Expo
Volition Sponsors Symposium at Veterinary Meeting and Expo PR Newswire
08.01.26 - PR Newswire
VolitionRx Secures $2.0 Million in Funding
VolitionRx Secures $2.0 Million in Funding PR Newswire
08.01.26 - PR Newswire
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats PR Newswire
17.12.25 - PR Newswire
Volition Issues Business Review 2025
Volition Issues Business Review 2025 PR Newswire
11.12.25 - PR Newswire
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment PR Newswire
08.12.25 - PR Newswire
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer PR Newswire
04.12.25 - PR Newswire
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-​World Evaluation of Early Detection of Sepsis PR Newswire
25.11.25 - PR Newswire
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use PR Newswire
13.11.25 - PR Newswire
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update PR Newswire
10.11.25 - PR Newswire
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update PR Newswire
17.10.25 - PR Newswire
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-​Assisted Crisis Response Dogs PR Newswire
10.10.25 - PR Newswire
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants PR Newswire
09.10.25 - PR Newswire
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »